Johnson & Johnson Total Assets
Johnson & Johnson total assets. Based on the latest financial reports, Johnson & Johnson (JNJ) holds total assets worth $192.82 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see JNJ company net worth for the company's overall valuation and market capitalisation.
Total Assets of Johnson & Johnson (1985–2024)
Total assets of Johnson & Johnson from 1985 to 2024. This chart illustrates how Johnson & Johnson's total assets have evolved over time, based on quarterly financial data. See latest Johnson & Johnson stock price today for real-time trading data and today's change.
Johnson & Johnson - Asset Composition Analysis
Johnson & Johnson Total Assets Breakdown (December 2024)
Johnson & Johnson total assets breakdown as of December 2024. Johnson & Johnson's total assets of $192.82 Billion consist of 31.0% current assets and 69.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $6.12 Billion | 13.4% |
| Accounts Receivable | $18.93 Billion | 10.5% |
| Inventory | $12.44 Billion | 6.9% |
| Property, Plant & Equipment | $21.62 Billion | 12.0% |
| Intangible Assets | $37.62 Billion | 20.9% |
| Goodwill | $44.20 Billion | 24.5% |
Asset Composition Trend (1985–2024)
This chart illustrates how Johnson & Johnson's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Johnson & Johnson to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Johnson & Johnson's current assets represent 31.0% of total assets in 2024, a decrease from 56.9% in 1985.
- Cash Position: Cash and equivalents constituted 13.4% of total assets in 2024, down from 14.4% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 24.5% of total assets.
Johnson & Johnson Competitors by Total Assets
Key competitors of Johnson & Johnson based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $115.70 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥12.85 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.71 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
Johnson & Johnson - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.07 | 1.03 | 1.21 |
| Quick Ratio | 0.80 | 0.79 | 0.99 |
| Cash Ratio | 0.10 | 0.09 | 0.00 |
| Working Capital | $3.74 Billion | $1.49 Billion | $8.74 Billion |
Johnson & Johnson - Advanced Valuation Insights
This section examines the relationship between Johnson & Johnson's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.25 |
| Latest Market Cap to Assets Ratio | 3.19 |
| Asset Growth Rate (YoY) | 7.5% |
| Total Assets | $180.10 Billion |
| Market Capitalization | $574.95 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Johnson & Johnson's assets at a significant premium (3.19x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Johnson & Johnson's assets grew by 7.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Johnson & Johnson (1985–2024)
The table below shows the annual total assets of Johnson & Johnson from 1985 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $180.10 Billion | +7.49% |
| 2023-12-31 | $167.56 Billion | -10.58% |
| 2022-12-31 | $187.38 Billion | +2.94% |
| 2021-12-31 | $182.02 Billion | +4.07% |
| 2020-12-31 | $174.89 Billion | +10.88% |
| 2019-12-31 | $157.73 Billion | +3.12% |
| 2018-12-31 | $152.95 Billion | -2.76% |
| 2017-12-31 | $157.30 Billion | +11.40% |
| 2016-12-31 | $141.21 Billion | +5.84% |
| 2015-12-31 | $133.41 Billion | +2.34% |
| 2014-12-31 | $130.36 Billion | -1.75% |
| 2013-12-31 | $132.68 Billion | +9.34% |
| 2012-12-31 | $121.35 Billion | +6.78% |
| 2011-12-31 | $113.64 Billion | +10.43% |
| 2010-12-31 | $102.91 Billion | +8.69% |
| 2009-12-31 | $94.68 Billion | +11.51% |
| 2008-12-31 | $84.91 Billion | +4.89% |
| 2007-12-31 | $80.95 Billion | +14.74% |
| 2006-12-31 | $70.56 Billion | +19.86% |
| 2005-12-31 | $58.86 Billion | +10.40% |
| 2004-12-31 | $53.32 Billion | +10.47% |
| 2003-12-31 | $48.26 Billion | +19.00% |
| 2002-12-31 | $40.56 Billion | +5.37% |
| 2001-12-31 | $38.49 Billion | +12.39% |
| 2000-12-31 | $34.24 Billion | +17.43% |
| 1999-12-31 | $29.16 Billion | +6.86% |
| 1998-12-31 | $27.29 Billion | +27.22% |
| 1997-12-31 | $21.45 Billion | +7.21% |
| 1996-12-31 | $20.01 Billion | +11.96% |
| 1995-12-31 | $17.87 Billion | +14.07% |
| 1994-12-31 | $15.67 Billion | +27.99% |
| 1993-12-31 | $12.24 Billion | +3.01% |
| 1992-12-31 | $11.88 Billion | +13.04% |
| 1991-12-31 | $10.51 Billion | +10.59% |
| 1990-12-31 | $9.51 Billion | +20.04% |
| 1989-12-31 | $7.92 Billion | +11.24% |
| 1988-12-31 | $7.12 Billion | +8.75% |
| 1987-12-31 | $6.55 Billion | +11.39% |
| 1986-12-31 | $5.88 Billion | +15.34% |
| 1985-12-31 | $5.10 Billion | -- |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bow… Read more